Beta

    fda approve camizestrant for advanced breast cancer

    Before Jan 1, 2028

    fda approve camizestrant for advanced breast cancer. Best Yes near 77¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 77¢ · Best No: 29¢ · 1 platform

    • Kalshi: Yes 77¢ / No 29¢
    LIVE

    Before Jan 1, 2028

    Volume

    $79

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jan 1, 2028

    ~564 days left

    Category

    Culture

    77¢CHANCE OF YES73%27%
    Yes
    77¢
    Kalshi
    No
    29¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    77¢
    No
    29¢
    Vol
    $79
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jan 1, 2028, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 77¢: exit costs ~1.24¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jan 1, 2028
    Time Left564 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In